Abstract
The role of muscarinic and nicotinic cholinergic receptors in analgesia and neuropathic pain relief is relatively unknown. This review describes how such drugs induce analgesia or alleviate neuropathic pain by acting on the central cholinergic system. Several pharmacological strategies are discussed which increase synthesis and release of acetylcholine (ACh) from cholinergic neurons. The effects of their acute and chronic administration are described. The pharmacological strategies which facilitate the physiological functions of the cholinergic system without altering the normal modulation of cholinergic signals are highlighted. It is proposed that full agonists of muscarinic or nicotinic receptors should be avoided. Their activation is too intense and un-physiological because neuronal signals are distorted when these receptors are constantly activated. Good results can be achieved by using agents that are able to a) increase ACh synthesis, b) partially inhibit cholinesterase activity c) selectively block the autoreceptor or heteroreceptor feedback mechanisms.
Activation of M1 subtype muscarinic receptors induces analgesia. Chronic stimulation of nicotinic (N1) receptors has neuronal protective effects. Recent experimental results indicate a relationship between repeated cholinergic stimulation and neurotrophic activation of the glial derived neurotrophic factor (GDNF) family. At least 9 patents covering novel chemicals for cholinergic system modulation and pain control are discussed.
Keywords: Artemin (ARTN), analgesia, cholinergic drugs, cholinergic system, glial-derived neurotrophic factor, muscarinic receptors, neuropathic pain, nicotinic receptors, Analgesic and Antineuropathic Drugs, Central Cholinergic Mechanisms
Recent Patents on CNS Drug Discovery (Discontinued)
Title: Analgesic and Antineuropathic Drugs Acting Through Central Cholinergic Mechanisms
Volume: 6 Issue: 2
Author(s): Alessandro Bartolini, Lorenzo Di Cesare Mannelli and Carla Ghelardini
Affiliation:
Keywords: Artemin (ARTN), analgesia, cholinergic drugs, cholinergic system, glial-derived neurotrophic factor, muscarinic receptors, neuropathic pain, nicotinic receptors, Analgesic and Antineuropathic Drugs, Central Cholinergic Mechanisms
Abstract: The role of muscarinic and nicotinic cholinergic receptors in analgesia and neuropathic pain relief is relatively unknown. This review describes how such drugs induce analgesia or alleviate neuropathic pain by acting on the central cholinergic system. Several pharmacological strategies are discussed which increase synthesis and release of acetylcholine (ACh) from cholinergic neurons. The effects of their acute and chronic administration are described. The pharmacological strategies which facilitate the physiological functions of the cholinergic system without altering the normal modulation of cholinergic signals are highlighted. It is proposed that full agonists of muscarinic or nicotinic receptors should be avoided. Their activation is too intense and un-physiological because neuronal signals are distorted when these receptors are constantly activated. Good results can be achieved by using agents that are able to a) increase ACh synthesis, b) partially inhibit cholinesterase activity c) selectively block the autoreceptor or heteroreceptor feedback mechanisms.
Activation of M1 subtype muscarinic receptors induces analgesia. Chronic stimulation of nicotinic (N1) receptors has neuronal protective effects. Recent experimental results indicate a relationship between repeated cholinergic stimulation and neurotrophic activation of the glial derived neurotrophic factor (GDNF) family. At least 9 patents covering novel chemicals for cholinergic system modulation and pain control are discussed.
Export Options
About this article
Cite this article as:
Bartolini Alessandro, Di Cesare Mannelli Lorenzo and Ghelardini Carla, Analgesic and Antineuropathic Drugs Acting Through Central Cholinergic Mechanisms, Recent Patents on CNS Drug Discovery (Discontinued) 2011; 6 (2) . https://dx.doi.org/10.2174/157488911795933901
DOI https://dx.doi.org/10.2174/157488911795933901 |
Print ISSN 1574-8898 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3954 |
Related Books
Related Articles
-
A Surgical Opinion on Hyperalgesia/Nociception, Inflammatory/Neurogenic Pain and Anti-inflammatory Responses and Drug Interventions Revisited: Current Breakthroughs and Views
Current Immunology Reviews (Discontinued) Predicting the Activity of ACE Inhibitory Peptides with a Novel Mode of Pseudo Amino Acid Composition
Protein & Peptide Letters Pharmacological Characteristics of Parenteral IGF-I Administration
Current Pharmaceutical Biotechnology Nanotechnology in Ophthalmic Drug Delivery: A Survey of Recent Developments and Patenting Activity
Recent Patents on Nanomedicine Evaluating the Safety and Tolerability of Azilsartan Medoxomil Alone or in Combination With Chlorthalidone in the Management of Hypertension: A Systematic Review
Current Hypertension Reviews Beta-Blocker Therapy for Septic Cardiac Shock: Fiction Or Realism?
Current Drug Therapy Protective Effects of Anesthetics on the Spinal Cord
Current Pharmaceutical Design The Renin-angiotensin System as a Target of Novel Anticancer Therapy
Current Pharmaceutical Design Vasopressin and Oxytocin in Control of the Cardiovascular System
Current Neuropharmacology Characterization and Antihypertensive Effect of the Complex of (-)-β- pinene in β-cyclodextrin
Current Pharmaceutical Biotechnology Classical Inhibitors of NOX NAD(P)H Oxidases Are Not Specific
Current Drug Metabolism “PARG Inhibitors’ Success: A Long Way to Go!”
Current Enzyme Inhibition Natriuretic Peptide Guided Heart Failure Management
Current Clinical Pharmacology Data-driven Approach to Detect and Predict Adverse Drug Reactions
Current Pharmaceutical Design Modern Treatment of Infection and Ischaemia to Reduce Major Amputation in the Diabetic Foot
Current Pharmaceutical Design Restoring the Dysfunctional Endothelium
Current Pharmaceutical Design Cytokines as Anti-Angiogenic Agents in Haematological Malignancies
Current Cancer Drug Targets Recent Advances and Approaches in Targeting Apoptosis Signaling Pathways for Anti-Cancer Therapeutics
Current Cancer Therapy Reviews Nicotine Addiction and Coronary Artery Disease: Impact of Cessation Interventions
Current Pharmaceutical Design Pharmacotherapy in Type 2 Diabetes: A Functional Schema for Drug Classification
Current Diabetes Reviews